Please wait while we load the requested 8-K report or click the link below:
https://last10k.com/sec-filings/report/1636651/000156459019023703/ovid-8k_20190627.htm
October 2023
August 2023
June 2023
May 2023
May 2023
April 2023
March 2023
March 2023
November 2022
August 2022
Please wait while we load the requested 8-K report or click the link below:
https://last10k.com/sec-filings/report/1636651/000156459019023703/ovid-8k_20190627.htm
Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Ovid Therapeutics Inc..
Ovid Therapeutics Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:
Material Contracts, Statements, Certifications & more
Ovid Therapeutics Inc. provided additional information to their SEC Filing as exhibits
Ticker: OVIDEvents:
CIK: 1636651
Form Type: 8-K Corporate News
Accession Number: 0001564590-19-023703
Submitted to the SEC: Thu Jun 27 2019 12:04:02 PM EST
Accepted by the SEC: Thu Jun 27 2019
Period: Thursday, June 27, 2019
Industry: Pharmaceutical Preparations